Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 3, 2000, Pages 568-574

  Fugère, Pierre ^a   Scheele, Wim H ^b   Shah, Aarti ^b   Strack, Thomas R ^b   Glant, Michael D ^c   Jolly, Elaine ^d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ELI LILLY AND COMPANY   (United States)

^c Diagnostic Cytology Laboratories Inc   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Continuous combined hormone replacement therapy; Endometrial biopsy; Raloxifene; Transvaginal ultrasonography; Uterus

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENDOMETRIUM BIOPSY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSVAGINAL ECHOGRAPHY; UTERUS;

EID: 0006552096     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.104768     Document Type: Article

References (27)

1. 1. PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
2. 2. PEPI Trial Writing Group. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996;275:370-5.
3. 3. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994;170:1213-23.
4. 4. Beresfoid SA, Weiss NS, Voigt LF, McKnight BS. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-61.
5. 5. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate, The Menopause Study Group. Obstet Gynecol 1994; 83:685-92.
6. 6. Spencer CP, Cooper AJ, Whitehead MI. Management of abnormal bleeding in women receiving hormone replacement therapy. BMJ 1997;315:37-42.
7. 7. Lobo RA, Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995;173:982-9.
8. 8. Baynes KC, Compston JE. Selective oestrogen receptor modulators: A new paradigm for HRT. Curr Opin Obstet Gynecol 1998;10:189-92.
9. 9. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
10. 10. Nolvadex (tamoxifen citrate) [package insert]. Wilmington [DE]: Zeneca Phartnaceuticals; 1998.
11. 11. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
12. 12. Barakat RR. Tamoxifen and the endometrium. Cancer Treat Res 1998;94:195-207.
13. 13. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-21.
14. 14. Dijkhuizen FP, Brolmann HA, Oddens BJ, Roumen RM, Coebergh JW, Heintz AP. Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Maturitas 1996;25:43-50.
15. 15. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
16. 16. Ensrud K, Black D, Recker R, Harris S, Delmas P, Pols H, et al. The effect of 2 and 3 years of raloxifene on vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Bone 1998;23:S174.
17. 17. Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. In: Program/Proceedings of the American Society of Clinical Oncology, Thirty-fourth Annual Meeting; 1998 May 16-19; Los Angeles, California. Philadelphia: WB Saunders; 1998. p. 2a.
18. 18. Kurman RJ, Norris HJ. Endometrial hyperplasia and related cellular changes. In: Kurman RJ, ed. Blaustein’s pathology of the female genital tract. New York: Springer-Verlag; 1994. p. 411-27.
19. 19. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177: 1458-64.
20. 20. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42.
21. 21. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20.
22. 22. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81:660-4.
23. 23. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995;59:261-6.
24. 24. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK, A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95:95-103.
25. 25. Whitehead MI, Fraser D. The effects of estrogens and progestogens on the endometrium. Modern approach to treatment. Obstet Gynecol Clin North Am 1987;14:299-320.
26. 26. Davies GC, Huster WJ, Lu Y, Plouffe L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-65.
27. 27. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1443-51.